Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
October 10, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
Type:
Grant
Filed:
November 12, 2021
Date of Patent:
October 10, 2023
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Alexandra Nathalie Kopic, Werner Hoellriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
Abstract: Provided herein are Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format, which includes a human semm albumin (HSA) domain that increases its semm half-life. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, and thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
Type:
Application
Filed:
September 3, 2021
Publication date:
October 5, 2023
Applicant:
Takeda Pharmaceutical Company Limited
Inventors:
Robert B. DuBridge, Daniel J. Hicklin, Patricia A. Culp
Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.
Type:
Application
Filed:
February 2, 2023
Publication date:
September 21, 2023
Applicants:
National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
Abstract: The invention provides, inter alia, methods of reducing gastrointestinal immune related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods encompass administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, such as an anti-?4?7 integrin antibody, such vedolizumab or a related antibody.
Abstract: The present invention relates to compounds of formula I bearing a sulfoxoniumylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.
Type:
Application
Filed:
December 20, 2019
Publication date:
September 14, 2023
Applicant:
Takeda Pharmaceutical Company Limited
Inventors:
Laura EDGINGTON-MITCHELL, Simon MOUNTFORD, Bethany M. ANDERSON, Monika SZABO, Luigi AURELIO, Philip THOMPSON
Abstract: Methods for quantitation of fC1-INH from dried blood spot are provided herein. Such methods may comprise spotting and drying a blood sample on a support member, extracting protein from the dried blood sample and measuring the level of fC1-INH in the extracted proteins.
Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
Abstract: The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
Type:
Grant
Filed:
March 16, 2021
Date of Patent:
September 5, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Antara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)·0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
September 5, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Kentaro Iwata, Masahiro Mizuno, Kazuhiro Maeda, Tsuneo Yasuma, Misaki Homma, Yuya Oguro, Naohiro Taya, Lei Zhu, John Daniel Bailey, Marianne Langston, Siddhesh Dinanath Patil, Shruti Gour, Lilly Roy
Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
September 5, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
September 5, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.
Type:
Grant
Filed:
July 13, 2021
Date of Patent:
September 5, 2023
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Kameswara Rao Kuchimanchi, Alexandra Loew-Baselli, Gerald Spotts, Myungshin Oh, Michael Don Hale, Martin Wolfsegger
Abstract: The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1?-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.
Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
August 22, 2023
Assignee:
Takeda Vaccines, Inc.
Inventors:
Jill A Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Sushma Kommareddy
Abstract: The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.
Type:
Grant
Filed:
April 27, 2022
Date of Patent:
August 15, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
He Xu, Hong Myung Lee, Christopher Arendt
Abstract: The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a ? and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like.